Article
Since a first symposium on neuroprotection was held at the Associationfor Research in Vision and Ophthalmology (ARVO) meeting 5 years ago, therehave been significant advances in understanding about the mechanisms fordeath of retinal neurons and in the development of neuroprotective therapiesfor glaucoma and other neurodegenerative diseases. At the 2004 annual ARVOmeeting, a panel of leading researchers provided an update on that progressin a symposium entitled "Neuroprotection: Where Are We Now".